RU96122169A - NON-SPLICING OPTIONS GP350 / 220 - Google Patents

NON-SPLICING OPTIONS GP350 / 220

Info

Publication number
RU96122169A
RU96122169A RU96122169/13A RU96122169A RU96122169A RU 96122169 A RU96122169 A RU 96122169A RU 96122169/13 A RU96122169/13 A RU 96122169/13A RU 96122169 A RU96122169 A RU 96122169A RU 96122169 A RU96122169 A RU 96122169A
Authority
RU
Russia
Prior art keywords
homogeneous
protein
amino acids
dna sequence
nucleotide
Prior art date
Application number
RU96122169/13A
Other languages
Russian (ru)
Other versions
RU2178807C2 (en
Inventor
Спает Ричард
Т.Джекмэн Винтроп
Original Assignee
Авирон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авирон filed Critical Авирон
Publication of RU96122169A publication Critical patent/RU96122169A/en
Application granted granted Critical
Publication of RU2178807C2 publication Critical patent/RU2178807C2/en

Links

Claims (10)

1. Выделенная ДНК последовательность, которая кодирует экспрессию гомогенного gр350 протеина.1. An isolated DNA sequence that encodes the expression of homogeneous gp350 protein. 2. ДНК последовательность по п.1, отличающаяся тем, что содержит нуклеотидную последовательность, в которой, по крайней мере, один нативный нуклеотид, кодирующий серин в положении 501 на фиг.1, заменен ненативным нуклеотидом, и в которой, по крайней мере, один нативный нуклеотид, кодирующий глицин в положении 698, заменен ненативным нуклеотидом. 2. The DNA sequence according to claim 1, characterized in that it contains a nucleotide sequence in which at least one native nucleotide encoding a serine at position 501 of FIG. 1 is replaced by a non-native nucleotide, and in which at least one native nucleotide encoding glycine at position 698 is replaced by a non-native nucleotide. 3. ДНК последовательность по п. 1, отличающаяся тем, что указанный гомогенный gр350 протеин дополнительно отличается тем, что кодирует аминокислотную последовательность, выбранную из группы, состоящей из: (а) аминокислот 19-862 на фиг. 1, (b) аминокислот 1-862 на фиг.1, (с) аминокислот 19-862 и аминокислот 882-907 на фиг. 1, (d) аминокислот 1-862 и аминокислот 882-907 на фиг. 1, (е) аминокислот 1-907, где нуклеотиды, кодирующие, по крайней мере, 8 аминокислот в трансмембранном участке, подверглись делеции. 3. The DNA sequence of claim 1, wherein said homogeneous gp350 protein is further characterized in that it encodes an amino acid sequence selected from the group consisting of: (a) amino acids 19-862 in FIG. 1, (b) amino acids 1-862 in FIG. 1, (c) amino acids 19-862 and amino acids 882-907 in FIG. 1, (d) amino acids 1-862 and amino acids 882-907 in FIG. 1, (e) amino acids 1-907, where nucleotides encoding at least 8 amino acids in the transmembrane region were deleted. 4. Вектор, содержащий ДНК последовательность по п. 1, 2 или 3. 4. A vector containing the DNA sequence of claim 1, 2 or 3. 5. Клетка хозяина, трансформированная ДНК последовательностью по п. 1, 2 или 3, оперативно связанной с последовательностью, контролирующей экспрессию, способной управлять репликацией и экспрессией указанной ДНК последовательности. 5. A host cell transformed with a DNA sequence according to claim 1, 2 or 3, operably linked to an expression control sequence capable of controlling the replication and expression of said DNA sequence. 6. Способ получения гомогенного gр350 протеина, включающий культивирование клеток хозяина по п. 5 в подходящей культуральной среде, и выделение указанного гомогенного gр350 протеина из указанных клеток. 6. A method for producing a homogeneous gp350 protein, comprising culturing the host cells according to claim 5 in a suitable culture medium, and isolating said homogeneous gp350 protein from said cells. 7. Гомогенный протеин gр350, полученный способом по п. 6. 7. Homogeneous protein gp350 obtained by the method according to p. 6. 8. Гомогенный gр350 протеин, отличающийся тем, что в нем один или более из нативных олигонуклеотидов, кодирующих донорный сплайсинговый сайт и акцепторный сплайсинговый сайт, заменен замещающим нуклеотидом (нуклеотидами) отличным от указанного нативного нуклеотида (нуклеотидов), который сохраняет аминокислотную последовательность указанного донорного и акцепторного сайтов. 8. Homogeneous gp350 protein, characterized in that in it one or more of the native oligonucleotides encoding the donor splicing site and the acceptor splicing site is replaced by a substituting nucleotide (s) different from said native nucleotide (s), which preserves the amino acid sequence of said donor and acceptor sites. 9. Фармацевтическая композиция, отличающаяся тем, что включает гомогенный gр350 протеин по п.7 или 8 в смеси с фармацевтически приемлемым носителем. 9. A pharmaceutical composition, characterized in that it comprises a homogeneous gp350 protein according to claim 7 or 8, mixed with a pharmaceutically acceptable carrier. 10. Применение гомогенного gр350 протеина для получения фармацевтической композиции, пригодной для профилактического лечения EBV-связанных заболеваний или состояний. 10. The use of homogeneous gp350 protein to obtain a pharmaceutical composition suitable for the prophylactic treatment of EBV-related diseases or conditions.
RU96122169/13A 1994-04-18 1995-04-13 Isolated dna sequence, vector, method of preparing homogeneous protein gp 350, homogeneous protein gp 350, pharmaceutical composition for treatment of ebv-mediated disease or state RU2178807C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
US08/229,291 1994-04-18

Publications (2)

Publication Number Publication Date
RU96122169A true RU96122169A (en) 2000-02-20
RU2178807C2 RU2178807C2 (en) 2002-01-27

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96122169/13A RU2178807C2 (en) 1994-04-18 1995-04-13 Isolated dna sequence, vector, method of preparing homogeneous protein gp 350, homogeneous protein gp 350, pharmaceutical composition for treatment of ebv-mediated disease or state

Country Status (25)

Country Link
US (3) US6054130A (en)
EP (1) EP0769056B1 (en)
JP (4) JP3447743B2 (en)
KR (1) KR100380953B1 (en)
CN (2) CN100415895C (en)
AT (1) ATE210184T1 (en)
AU (1) AU707837B2 (en)
BR (1) BR9507473A (en)
CA (1) CA2187908C (en)
CZ (1) CZ292283B6 (en)
DE (1) DE69524415T2 (en)
DK (1) DK0769056T3 (en)
ES (1) ES2170144T3 (en)
FI (2) FI118224B (en)
HU (1) HU221647B1 (en)
LV (1) LV11803B (en)
MY (1) MY114769A (en)
NO (1) NO319382B1 (en)
PL (1) PL181881B1 (en)
PT (1) PT769056E (en)
RU (1) RU2178807C2 (en)
SK (1) SK283446B6 (en)
TW (1) TW496897B (en)
UA (1) UA47403C2 (en)
WO (1) WO1995028488A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
WO1997033551A2 (en) * 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
EP1086231A2 (en) * 1998-06-12 2001-03-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
WO2010135514A2 (en) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069310D1 (en) * 1980-11-03 1984-10-31 Itt Ind Gmbh Deutsche Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3583564D1 (en) * 1984-08-23 1991-08-29 Hans Joachim Wolf DNA SEQUENCES OF THE EBV GENOME, RECOMBINANT DNA MOLECULES, METHOD FOR THE PRODUCTION OF EBV-RELATED ANTIGENS, DIAGNOSTIC COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ANTIGENS.
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Similar Documents

Publication Publication Date Title
Doorbar et al. Identification of the human papilloma virus‐1a E4 gene products.
DK257984D0 (en) PROCEDURE FOR THE PREPARATION OF A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR
EP0279582A3 (en) Dna sequences to target proteins to the mammary gland for efficient secretion
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
AU6964191A (en) Particle-mediated transformation of animal tissue cells
WO1999029871A3 (en) Circovirus sequences related to piglet weight loss disease (pwd)
EA200100670A1 (en) METHOD OF HIGH-PRODUCTIVE EXPRESSION OF ACTIVE CHIMERIC PROTEINS OF LYMPHOTOXIN-B RECEPTOR; And immunoglobulin and their excretion
AU5020296A (en) C-C chemokine receptor 3: CKR-3 or EOS-l2
AU7284287A (en) Recombinant vaccinia virus expressing human retrovirus gene
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
WO2000034474A3 (en) Growth factor homolog zvegf3
Milhausen et al. Caulobacter flagellin mRNA segregates asymmetrically at cell division
RU96122169A (en) NON-SPLICING OPTIONS GP350 / 220
CA2207815A1 (en) Modulators of the function of fas/apo1 receptors
RU95115686A (en) PREMERSACIDINE, PROMERSACIDINE, DNA, VECTOR, HOST CELL, METHOD FOR PRODUCING
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
AU657698B2 (en) Method for modifying the cell, tissue or host tropism of a microorganism; recombinant microorganisms obtained in this way and use thereof in medicine and veterinary medicine
KR920004571A (en) Gene encoding heparin binding neurotrophic factor (HBNF), expression vectors and host cells comprising the same, and methods for producing and using HBNF
KR970705408A (en) Haemophilus adhesion and penetration proteins (HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS)
KR910006483A (en) Genetic engineering methods using microorganisms of recombinant aprotinin variants, homogeneously processed aprotinin variants, and therapeutic uses thereof
WO1997007135A3 (en) Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
KR880002894A (en) Protein and DNA sequence used as a chemobacteremia wax
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
KR100380953B1 (en) Unsplit variant of gp350 / 220
EP0811685A3 (en) Human platelet-derived growth factor receptors